Cost-Effectiveness Model Comparing Olanzapine and Other Oral Atypical Antipsychotics in the Treatment of Schizophrenia in the United States

Cost Effectiveness and Resource Allocation - United Kingdom
doi 10.1186/1478-7547-7-4
Full Text
Abstract

Available in full text

Categories
Health Policy
Date
Authors
Publisher

Springer Science and Business Media LLC